Randomized clinical trials have shown adding oxaliplatin to adjuvant 5FU improves outcomes of patients with stage III colon cancer, but researchers set out to determine its effectiveness in the general population, which is usually older, sicker and more racially diverse than patients who enroll in trials.
Using data from the Surveillance, Epidemiology, and End Results registry linked to Medicare claims and other cancer registries, Hanna K. Sanoff, MD, assistant professor of medicine, hematology and oncology at the University of Virginia School of Medicine and colleagues, found adding oxaliplatin to adjuvant 5FU was just as effective in the general population as in randomized clinical trials.
Related Articles on Colon Cancer:
New Test Offers Greater Accuracy in Early Detection of Colorectal Cancer
Bayer Seeks FDA Approval for First New Drug to Treat Colorectal Cancer in 5 Years
The Colon Cancer Screening Controversy: How Old is Too Old to Screen?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
